Annual Report FY 2024-25
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Chemo Pharma Laboratories Limited (BSE: 506365) has filed its Annual Report for FY 2024-25 along with the Notice of its 83rd Annual General Meeting scheduled for September 24, 2025 via video conferencing. Key business items at the AGM include a proposed change of company name to 'Starsource Multitrade Limited' and a complete overhaul of the Object Clause, shifting the core business from pharmaceuticals to general trading, import/export, brokering, and dealing in all types of goods and commodities. The company is also seeking shareholder approval to regularize Mr. Ruchit Mehta as Managing Director & CEO and Mr. Utsav Trivedi as Executive Director & CFO, both for five-year terms, along with regularization of three independent directors. Additionally, a promoter group shareholder (Ms. Shanta Somani, holding nil shares) is being reclassified as a public shareholder.
This filing signals a major strategic pivot for the company, moving away from its legacy pharmaceutical business toward a trading and multi-commerce model. The proposed rebranding to 'Starsource Multitrade Limited' and complete change in business objects could materially reshape the company's revenue profile and risk characteristics, and shareholders should carefully evaluate the rationale before voting at the AGM.